PATENT CLAIM ANALYSIS

Application Number: 16185384
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["424", "450000"]

Abstract:
Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

Claim (Index 6):
The method of  claim 5 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC).

Metadata:
- Claim Count in Document: 23.0
- Percentile: 98.0
- Lexical Diversity: 1.62222
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10696389', '14319018', '14987508', '15241439', '12748756']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6350693355361234
- 35 USC 102 Novelty (BERT): 0.5041507148391576
- Combined Prediction Score: 0.6219774734664268
- Mean Citation Score: 225.18291
- Max Citation Score: 246.9306
- Similarity Product: 188.9684023435593

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test